Navigating the Long-Term Use of Proton Pump Inhibitors: Clinical Efficacy and Safety Concerns

ABSTRACT:
Proton pump inhibitors (PPIs) have been extensively used for over two decades as the cornerstone
therapy for acid-related gastrointestinal disorders, including gastroesophageal reflux disease,
peptic ulcer disease, and Zollinger-Ellison syndrome. Their clinical efficacy in suppressing
gastric acid secretion and promoting mucosal healing is well established. However, widespread
and often prolonged use has prompted growing concerns regarding safety issues associated with
long-term therapy. This article provides a comprehensive review of the current evidence on the
clinical benefits and potential risks of extended PPI use. Common adverse effects such as nutrient
malabsorption (magnesium, calcium, vitamin B12), increased susceptibility to infections
(Clostridioides difficile, pneumonia), renal complications, and possible cardiovascular and
gastrointestinal risks are discussed in detail. The role of pharmacovigilance data in monitoring
these safety concerns is highlighted. Additionally, evidence-based deprescribing strategies are
presented to guide appropriate tapering and discontinuation of PPIs when long-term use is not
warranted. The critical involvement of clinicians and pharmacists in ensuring rational prescribing,
patient education, and adverse effect management is emphasized. Lifestyle modifications that
may reduce dependence on pharmacologic therapy are also reviewed. This balanced overview
underscores the importance of individualized therapy, regular reassessment, and interdisciplinary
collaboration to optimize patient outcomes while minimizing adverse events related to long-term
PPI therapy.